DE69923849D1 - Quinolin-2-on-derivate verwendbar als antikrebsmittel - Google Patents
Quinolin-2-on-derivate verwendbar als antikrebsmittelInfo
- Publication number
- DE69923849D1 DE69923849D1 DE69923849T DE69923849T DE69923849D1 DE 69923849 D1 DE69923849 D1 DE 69923849D1 DE 69923849 T DE69923849 T DE 69923849T DE 69923849 T DE69923849 T DE 69923849T DE 69923849 D1 DE69923849 D1 DE 69923849D1
- Authority
- DE
- Germany
- Prior art keywords
- formula
- compounds
- anticrophosis
- quinolin
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9813698P | 1998-08-27 | 1998-08-27 | |
| US98136P | 1998-08-27 | ||
| PCT/IB1999/001393 WO2000012498A1 (en) | 1998-08-27 | 1999-08-05 | Quinolin-2-one derivatives useful as anticancer agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69923849D1 true DE69923849D1 (de) | 2005-03-31 |
| DE69923849T2 DE69923849T2 (de) | 2006-01-12 |
Family
ID=22267419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69923849T Expired - Fee Related DE69923849T2 (de) | 1998-08-27 | 1999-08-05 | Quinolin-2-on-derivate verwendbar als antikrebsmittel |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6495564B1 (de) |
| EP (1) | EP1107962B1 (de) |
| JP (1) | JP3494409B2 (de) |
| AT (1) | ATE289602T1 (de) |
| AU (1) | AU4925199A (de) |
| BR (1) | BR9913315A (de) |
| CA (1) | CA2341739C (de) |
| DE (1) | DE69923849T2 (de) |
| ES (1) | ES2237125T3 (de) |
| GT (1) | GT199900139A (de) |
| MA (1) | MA26679A1 (de) |
| PA (1) | PA8480201A1 (de) |
| TN (1) | TNSN99161A1 (de) |
| UY (1) | UY25679A1 (de) |
| WO (1) | WO2000012498A1 (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2262626T3 (es) * | 2000-02-04 | 2006-12-01 | Janssen Pharmaceutica N.V. | Inhibidores de farnesil proteina transferasa para tratar cancer de mama. |
| DE60130976T2 (de) | 2000-02-24 | 2008-07-17 | Janssen Pharmaceutica N.V. | Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs |
| JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
| AU2001293835A1 (en) * | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
| ATE321038T1 (de) | 2000-09-25 | 2006-04-15 | Janssen Pharmaceutica Nv | Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren |
| ES2313991T3 (es) * | 2000-09-25 | 2009-03-16 | Janssen Pharmaceutica Nv | Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa. |
| WO2002024683A1 (en) * | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives |
| BR0114253A (pt) * | 2000-10-02 | 2003-07-01 | Janssen Pharmaceutica Nv | Antagonistas de receptor de glutamato metabotrópico |
| ES2328225T3 (es) | 2000-11-21 | 2009-11-11 | Janssen Pharmaceutica Nv | Derivados benzoheterociclicos inhibidores de la farnesil-transferasa. |
| US20020115640A1 (en) * | 2000-11-30 | 2002-08-22 | Claiborne Akiyo K. | Farnesyltransferase inhibitors |
| US7211595B2 (en) | 2000-11-30 | 2007-05-01 | Abbott Laboratories | Farnesyltransferase inhibitors |
| WO2002051835A1 (en) * | 2000-12-27 | 2002-07-04 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| AU2002236813A1 (en) * | 2001-01-22 | 2002-07-30 | Schering Corporation | Treatment of malaria with farnesyl protein transferase inhibitors |
| JP4257698B2 (ja) | 2001-03-12 | 2009-04-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | イミダゾール化合物の製造方法 |
| AU2002257114A1 (en) * | 2001-04-06 | 2002-10-21 | Schering Corporation | Treatment of malaria with farsenyl protein transferase inhibitors |
| WO2003000705A1 (en) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinolines and uses thereof |
| WO2003000266A1 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinolines and uses thereof |
| WO2003051880A1 (en) | 2001-12-19 | 2003-06-26 | Janssen Pharmaceutica N.V. | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
| EP1490065B1 (de) | 2002-03-22 | 2007-06-13 | Janssen Pharmaceutica N.V. | Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren |
| NZ535438A (en) * | 2002-03-29 | 2006-08-31 | Janssen Pharmaceutica Nv | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| AU2003229688B2 (en) | 2002-04-15 | 2009-07-30 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
| JP3814285B2 (ja) * | 2002-12-19 | 2006-08-23 | ファイザー・インク | 眼疾患の治療に有用なプロテインキナーゼ阻害剤としての２−（１ｈ−インダゾール−６−イルアミノ）−ベンズアミド化合物 |
| JP4691041B2 (ja) | 2003-11-20 | 2011-06-01 | チルドレンズ ホスピタル メディカル センター | Ｇｔｐアーゼ阻害剤および使用方法 |
| BRPI0509580A (pt) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
| JP2008510792A (ja) * | 2004-08-26 | 2008-04-10 | ファイザー・インク | タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
| ATE463486T1 (de) | 2004-08-26 | 2010-04-15 | Pfizer | Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer |
| CN101018780B (zh) * | 2004-08-26 | 2012-01-11 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的吡唑取代的氨基杂芳基化合物 |
| EP1815247B1 (de) | 2004-11-05 | 2013-02-20 | Janssen Pharmaceutica NV | Therapeutische verwendung von farnesyltransferase-hemmern und verfahren zur überwachung der wirksamkeit |
| US20060107555A1 (en) * | 2004-11-09 | 2006-05-25 | Curtis Marc D | Universal snow plow adapter |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US7826982B2 (en) | 2005-07-29 | 2010-11-02 | Children's Hospital Medical Center | Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE |
| UA94060C2 (ru) | 2005-09-07 | 2011-04-11 | Эмджен Фримонт Инк. | Моноклональное антитело, которое специфически связывает alk-1 |
| WO2007035744A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| MX2008013533A (es) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Compuestos heterociclicos como inhibidores de c-fms cinasa. |
| JP5331681B2 (ja) | 2006-04-20 | 2013-10-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ｃ−ｆｍｓキナーゼの阻害剤 |
| EP2441472B1 (de) | 2006-08-21 | 2015-06-10 | F. Hoffmann-La Roche AG | Tumortherapie mit einem Anti-VEGF-Antikörper |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
| WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2013527748A (ja) | 2010-03-03 | 2013-07-04 | オーエスアイ・ファーマシューティカルズ，エルエルシー | インスリン様増殖因子１受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー |
| US20110217309A1 (en) | 2010-03-03 | 2011-09-08 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US9980942B2 (en) | 2012-05-02 | 2018-05-29 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
| EP2882757B1 (de) | 2012-08-07 | 2016-10-05 | Janssen Pharmaceutica, N.V. | Verfahren zur herstellung heterocyclischer esterderivate |
| JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
| WO2016187544A1 (en) * | 2015-05-20 | 2016-11-24 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing cancer |
| DK3277842T5 (da) | 2015-08-17 | 2020-08-31 | Kura Oncology Inc | Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer |
| JP6877429B2 (ja) | 2015-12-03 | 2021-05-26 | アジオス ファーマシューティカルズ， インコーポレイテッド | Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤 |
| US20190119758A1 (en) | 2016-04-22 | 2019-04-25 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
| US11124839B2 (en) | 2016-11-03 | 2021-09-21 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| US10137121B2 (en) | 2017-02-21 | 2018-11-27 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| EP3432883B1 (de) | 2017-02-21 | 2021-07-28 | Kura Oncology, Inc. | Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren |
| US10806730B2 (en) | 2017-08-07 | 2020-10-20 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| BR112020002591A2 (pt) | 2017-08-07 | 2020-07-28 | Kura Oncology, Inc. | método para o tratamento de câncer |
| WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| EP3873469A2 (de) | 2018-11-01 | 2021-09-08 | Kura Oncology, Inc. | Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren |
| EP3897638A1 (de) | 2018-12-21 | 2021-10-27 | Kura Oncology, Inc. | Therapien für plattenepithelkarzinome |
| US20220142983A1 (en) | 2019-03-01 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| TW202108170A (zh) | 2019-03-15 | 2021-03-01 | 美商庫拉腫瘤技術股份有限公司 | 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法 |
| JP2022527495A (ja) | 2019-03-29 | 2022-06-02 | クラ オンコロジー， インコーポレイテッド | ファルネシルトランスフェラーゼ阻害剤による扁平上皮癌の治療方法 |
| TW202102218A (zh) | 2019-04-01 | 2021-01-16 | 美商庫拉腫瘤技術股份有限公司 | 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法 |
| WO2020223583A1 (en) | 2019-05-02 | 2020-11-05 | Kura Oncology, Inc. | Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors |
| WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2002864C (en) * | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| CA2231105C (en) * | 1995-12-08 | 2005-09-13 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
| TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| CA2290992C (en) * | 1997-06-02 | 2008-02-12 | Janssen Pharmaceutica N.V. | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
| JP3495706B2 (ja) * | 1998-08-27 | 2004-02-09 | ファイザー・プロダクツ・インク | 抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体 |
-
1999
- 1999-08-05 WO PCT/IB1999/001393 patent/WO2000012498A1/en active IP Right Grant
- 1999-08-05 AT AT99933080T patent/ATE289602T1/de not_active IP Right Cessation
- 1999-08-05 DE DE69923849T patent/DE69923849T2/de not_active Expired - Fee Related
- 1999-08-05 JP JP2000567526A patent/JP3494409B2/ja not_active Expired - Fee Related
- 1999-08-05 CA CA002341739A patent/CA2341739C/en not_active Expired - Fee Related
- 1999-08-05 ES ES99933080T patent/ES2237125T3/es not_active Expired - Lifetime
- 1999-08-05 AU AU49251/99A patent/AU4925199A/en not_active Abandoned
- 1999-08-05 EP EP99933080A patent/EP1107962B1/de not_active Expired - Lifetime
- 1999-08-05 BR BR9913315-6A patent/BR9913315A/pt not_active Application Discontinuation
- 1999-08-10 PA PA19998480201A patent/PA8480201A1/es unknown
- 1999-08-20 GT GT199900139A patent/GT199900139A/es unknown
- 1999-08-25 TN TNTNSN99161A patent/TNSN99161A1/fr unknown
- 1999-08-25 MA MA25742A patent/MA26679A1/fr unknown
- 1999-08-26 US US09/384,339 patent/US6495564B1/en not_active Expired - Fee Related
- 1999-08-27 UY UY25679A patent/UY25679A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP3494409B2 (ja) | 2004-02-09 |
| ATE289602T1 (de) | 2005-03-15 |
| EP1107962A1 (de) | 2001-06-20 |
| PA8480201A1 (es) | 2000-09-29 |
| UY25679A1 (es) | 2000-03-31 |
| MA26679A1 (fr) | 2004-12-20 |
| AU4925199A (en) | 2000-03-21 |
| JP2002523503A (ja) | 2002-07-30 |
| CA2341739A1 (en) | 2000-03-09 |
| TNSN99161A1 (fr) | 2005-11-10 |
| BR9913315A (pt) | 2001-05-22 |
| GT199900139A (es) | 2001-02-10 |
| ES2237125T3 (es) | 2005-07-16 |
| WO2000012498A1 (en) | 2000-03-09 |
| EP1107962B1 (de) | 2005-02-23 |
| DE69923849T2 (de) | 2006-01-12 |
| US6495564B1 (en) | 2002-12-17 |
| CA2341739C (en) | 2005-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69923849D1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
| AP2001002079A0 (en) | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents. | |
| AP1895A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents. | |
| BG104998A (en) | Isothiazole derivatives useful as anticancer agents | |
| MY124390A (en) | Substituted bicyclic derivatives useful as anticancer agents | |
| AP9701039A0 (en) | Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one. | |
| BG105860A (en) | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | |
| PT928788E (pt) | Compostos farmaceuticamente activos | |
| YU95102A (sh) | Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija | |
| MY139357A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| PT1029853E (pt) | Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos | |
| BRPI0413876A (pt) | tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos | |
| TW375615B (en) | Galanthamine derivatives and their use as medicaments | |
| TNSN02096A1 (en) | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth | |
| AP9901559A0 (en) | Tricyclic 3-keto derivatives of 6-0-methylerythromycin. | |
| ECSP993117A (es) | Derivados de quinolin -2 - ona utiles como agentes contra el cancer | |
| TR200102315T2 (tr) | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2- on türevleri. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |